London– Aktiia, a health technology company specializing in blood pressure monitoring, has raised $42 million in an oversubscribed Series B funding round and announced a corporate rebrand to Hilo, signaling a new phase in its mission to make blood pressure management easier and more accessible worldwide.
The round was co-led by Earlybird Health and Wellington Partners, with participation from new investors Kfund and naturalX Health Ventures, as well as existing backers including Khosla Ventures, Molten Ventures, redalpine, Translink Capital, and Verve Ventures. The latest investment brings Hilo’s total funding to more than $100 million.
With the new capital, Hilo plans to accelerate product innovation, expand into global markets, and further develop its proprietary blood pressure intelligence platform for enterprise applications. The funding comes on the heels of a strong growth period, during which the company secured CE marking for its mobile phone-based blood pressure technology, regulatory approvals in Canada, Australia, and Saudi Arabia, and completed a pivotal clinical trial in preparation for FDA submission in the U.S. The company also reported 76% annual revenue growth.
“This funding round reflects the confidence our investors have in Hilo’s mission and breakthrough technology,” said Raghav “Rags” Gupta, CEO of Hilo. “With only 20% of people with hypertension having their blood pressure under control, the need for more convenient and accurate monitoring has never been greater. Our rebrand marks a new era of empowering users globally to take charge of their health.”
As part of its transformation, Hilo is rolling out a new brand identity that underscores its ambition to make cuffless, clinically validated blood pressure monitoring both effortless and widely available. The company’s platform is built around a proprietary machine learning model trained on tens of billions of optical signals and hundreds of millions of calibration points—technology that has powered more than 120,000 devices sold to date.
“Hilo sits at the intersection of clinical precision and everyday accessibility,” said Christoph Massner, Principal at Earlybird Health, who will join the company’s board. “It’s a rare combination that addresses one of the world’s most urgent medical needs: uncontrolled high blood pressure.”
Johannes Fischer, Managing Partner at Wellington Partners, added, “Hilo’s innovation promises to transform how we monitor and manage one of the most common health risks, bringing real-time blood pressure insights to users around the world.”
The rebrand to Hilo positions the company as a leader in the emerging cuffless blood pressure monitoring (CBPM) market, as it continues to push toward universal access to smarter cardiovascular health solutions.
